Pediatric Growth Hormone Deficiency - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Pediatric Growth Hormone Deficiency - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pediatric Growth Hormone Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pediatric Growth Hormone Deficiency: Overview
Growth hormone deficiency (GHD) is caused when the pituitary gland or the hypothalamus is not functioning properly and does not produce enough growth hormone. GHD can be acquired or congenital. Children with GHD have abnormally short stature with normal body proportions. GHD affects male and female equally. Symptoms include slow growth, delayed sexual development, and others.
“Pediatric Growth Hormone Deficiency - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pediatric Growth Hormone Deficiency pipeline landscape is provided which includes the disease overview and Pediatric Growth Hormone Deficiency treatment guidelines. The assessment part of the report embraces, in depth Pediatric Growth Hormone Deficiency commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pediatric Growth Hormone Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pediatric Growth Hormone Deficiency R&D. The therapies under development are focused on novel approaches to treat/improve Pediatric Growth Hormone Deficiency.
Pediatric Growth Hormone Deficiency Emerging Drugs Chapters
This segment of the Pediatric Growth Hormone Deficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pediatric Growth Hormone Deficiency Emerging Drugs
Lonapegsomatropin: Ascendis Pharma A/S
Lonapegsomatropin is a growth hormone. It is currently being developed for the treatment of growth hormone deficiency. The drug molecule works as a somatotropin receptor agonist. It is currently in pre-registration phase.
Somatrogon: OPKO Health
Somatrogon is a recombinant protein comprising of human growth hormone (hGh). It is a novel molecule with receptor binding properties and mechanism of action similar to hGh. The drug is in phase III and is developed for the treatment of growth hormone deficiency.
Further product details are provided in the report……..
Pediatric Growth Hormone Deficiency: Therapeutic Assessment
This segment of the report provides insights about the different Pediatric Growth Hormone Deficiency drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Pediatric Growth Hormone Deficiency
There are approx. 5+ key companies which are developing the therapies for Pediatric Growth Hormone Deficiency. The companies which have their Pediatric Growth Hormone Deficiency drug candidates in the most advanced stage, i.e. phase Pre-registration include, Ascendis Pharma A/S.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Pediatric Growth Hormone Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pediatric Growth Hormone Deficiency: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pediatric Growth Hormone Deficiency therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pediatric Growth Hormone Deficiency drugs.
Pediatric Growth Hormone Deficiency Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Pediatric Growth Hormone Deficiency - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pediatric Growth Hormone Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pediatric Growth Hormone Deficiency: Overview
Growth hormone deficiency (GHD) is caused when the pituitary gland or the hypothalamus is not functioning properly and does not produce enough growth hormone. GHD can be acquired or congenital. Children with GHD have abnormally short stature with normal body proportions. GHD affects male and female equally. Symptoms include slow growth, delayed sexual development, and others.
“Pediatric Growth Hormone Deficiency - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pediatric Growth Hormone Deficiency pipeline landscape is provided which includes the disease overview and Pediatric Growth Hormone Deficiency treatment guidelines. The assessment part of the report embraces, in depth Pediatric Growth Hormone Deficiency commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pediatric Growth Hormone Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pediatric Growth Hormone Deficiency R&D. The therapies under development are focused on novel approaches to treat/improve Pediatric Growth Hormone Deficiency.
Pediatric Growth Hormone Deficiency Emerging Drugs Chapters
This segment of the Pediatric Growth Hormone Deficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pediatric Growth Hormone Deficiency Emerging Drugs
Lonapegsomatropin: Ascendis Pharma A/S
Lonapegsomatropin is a growth hormone. It is currently being developed for the treatment of growth hormone deficiency. The drug molecule works as a somatotropin receptor agonist. It is currently in pre-registration phase.
Somatrogon: OPKO Health
Somatrogon is a recombinant protein comprising of human growth hormone (hGh). It is a novel molecule with receptor binding properties and mechanism of action similar to hGh. The drug is in phase III and is developed for the treatment of growth hormone deficiency.
Further product details are provided in the report……..
Pediatric Growth Hormone Deficiency: Therapeutic Assessment
This segment of the report provides insights about the different Pediatric Growth Hormone Deficiency drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Pediatric Growth Hormone Deficiency
There are approx. 5+ key companies which are developing the therapies for Pediatric Growth Hormone Deficiency. The companies which have their Pediatric Growth Hormone Deficiency drug candidates in the most advanced stage, i.e. phase Pre-registration include, Ascendis Pharma A/S.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Pediatric Growth Hormone Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pediatric Growth Hormone Deficiency: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pediatric Growth Hormone Deficiency therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pediatric Growth Hormone Deficiency drugs.
Pediatric Growth Hormone Deficiency Report Insights
- Pediatric Growth Hormone Deficiency Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pediatric Growth Hormone Deficiency drugs?
- How many Pediatric Growth Hormone Deficiency drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pediatric Growth Hormone Deficiency?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pediatric Growth Hormone Deficiency therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pediatric Growth Hormone Deficiency and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ascendis Pharma
- OPKO Health
- Aravive
- Lonapegsomatropin
- Somatrogon
- VRS-317
Introduction
Executive Summary
Pediatric Growth Hormone Deficiency: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pediatric Growth Hormone Deficiency – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pediatric Growth Hormone Deficiency companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pediatric Growth Hormone Deficiency Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase Pre-registration)
Comparative Analysis
Lonapegsomatropin: Ascendis Pharma
Product Description
Research and Development
Product Development Activities
Late Stage Products (Phase III)
Comparative Analysis
Somatrogon: OPKO Health
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Pediatric Growth Hormone Deficiency Key Companies
Pediatric Growth Hormone Deficiency Key Products
Pediatric Growth Hormone Deficiency- Unmet Needs
Pediatric Growth Hormone Deficiency- Market Drivers and Barriers
Pediatric Growth Hormone Deficiency- Future Perspectives and Conclusion
Pediatric Growth Hormone Deficiency Analyst Views
Pediatric Growth Hormone Deficiency Key Companies
Appendix
Executive Summary
Pediatric Growth Hormone Deficiency: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pediatric Growth Hormone Deficiency – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pediatric Growth Hormone Deficiency companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pediatric Growth Hormone Deficiency Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase Pre-registration)
Comparative Analysis
Lonapegsomatropin: Ascendis Pharma
Product Description
Research and Development
Product Development Activities
Late Stage Products (Phase III)
Comparative Analysis
Somatrogon: OPKO Health
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Pediatric Growth Hormone Deficiency Key Companies
Pediatric Growth Hormone Deficiency Key Products
Pediatric Growth Hormone Deficiency- Unmet Needs
Pediatric Growth Hormone Deficiency- Market Drivers and Barriers
Pediatric Growth Hormone Deficiency- Future Perspectives and Conclusion
Pediatric Growth Hormone Deficiency Analyst Views
Pediatric Growth Hormone Deficiency Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Pediatric Growth Hormone Deficiency
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Pediatric Growth Hormone Deficiency
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Pediatric Growth Hormone Deficiency
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Pediatric Growth Hormone Deficiency
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
